# HUMAN MELANOMA, IMMUNOTHERAPY, ANTIIDIOTYPE

> **NIH NIH R01** · NEW YORK MEDICAL COLLEGE · 1989 · $168,614

## Abstract

Malignant transformation of human melanocytes may be associated with the
appearance of a high molecular weight-melanoma associated antigen
(HMW-MAA).  Since the HMW-MAA meets the criteria to be a useful target for
immunotherapy, this proposal aims at evaluating the usefulness of i)
heteroconjugates between anti HMW-MAA and anti T3 monoclonal antibodies and
of ii) anti HMW-MAA antiidiotype monoclonal antibodies to develop
immunotherapeutic approaches to melanoma.  Furthermore this proposal aims
at broadening the range of specificity of monoclonal antibodies to human
melanoma associated antigens (MAA).  Since immunization with immune
interferon treated melanoma cells has elicited for the first time
monoclonal antibodies to MAA with differential distribution in primary and
metastatic lesions, we plan to develop monoclonal antibodies utilizing mice
immunized with interferon treated melanoma cells.  Following an extensive
serological and immunochemical characterization the antibodies will be used
to characterize surgically removed lesions of melanocyte origin.  The
in-vitro data will be correlated with the clinical course of the disease.
Cell lines and surgically removed tissues will represent the antigen
sources.  Already available and newly developed hybridomas will represent
the antibody sources.  Immunochemical, cell mediated immunity and
immunohistochemical techniques will represent the assay systems.  The
results of these studies may suggest new therapeutic approaches to melanoma
and may identify new markers to evaluate the biological properties of
melanoma cells and the clinical course of the disease.

## Key facts

- **NIH application ID:** 3175938
- **Project number:** 5R01CA037959-06
- **Recipient organization:** NEW YORK MEDICAL COLLEGE
- **SAM.gov UEI:** WK63UJ11C2H7
- **Principal Investigator:** SOLDANO FERRONE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $168,614
- **Award type:** 5
- **Project period:** 1983-12-01 → 1992-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175938

## Citation

> US National Institutes of Health, RePORTER application 3175938, HUMAN MELANOMA, IMMUNOTHERAPY, ANTIIDIOTYPE (5R01CA037959-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175938. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*